ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Demographics, methods of use, and perceived benefits among patients with cancer who use cannabis.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to assess the demographics, reasons, methods, perceived benefits, and costs associated with the use of cannabis among patients with cancer.
methodsPaper and electronic surveys in English were offered to patients visiting select oncology offices in Northern California between February 2018 and May 2024. Questions gathered information on participants' demographics, cancer stage, chemotherapy status, methods, and reasons for cannabis use (e.g., appetite, nausea, sleep, pain), symptom severity ratings (1-10) before and after use, and monthly expenditure. Logistic regression analysis was used to compute odds ratios (OR) and 95% confidence intervals (95% CI).
resultsOf the 2602 completed surveys, 643 (24.7%) respondents reported using cannabis. Factors significantly associated with use included younger age (OR 0.96; 95% CI 0.95, 0.97), advanced cancer (Stage 4, OR 3.28; 95% CI 1.25, 8.61), and concurrent chemotherapy treatment (OR 2.45; 95% CI 1.80, 3.35). Non-Hispanic White race/ethnicity showed increased odds of use, whereas Hispanic (OR 0.61; CI 0.38, 0.98), Pacific Islander (OR 0.33; CI 0.17, 0.63), and Asian Indians (OR 0.34; CI 0.12, 0.92) had decreased odds. The primary reason for use was improving sleep (56.7%). Preferred methods included smoking/vaping (68%) and edibles (60%), with over 65% of users employing multiple methods. Patients consistently reported perceived symptom improvements, and most spent less than $100 per month.
conclusionWhile efficacy evidence remains limited, cancer patients in this cohort who used cannabis reported tangible benefits in symptom management. Controlled research is crucial to determine the clinical benefits and potential harms, enabling clinicians to provide informed guidance on safe and effective cannabis use.
Indexed as
Identifiers
41686327What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.